Alto Neuroscience Files 2025 Proxy Statement
Ticker: ANRO · Form: DEF 14A · Filed: Apr 1, 2025 · CIK: 1999480
| Field | Detail |
|---|---|
| Company | Alto Neuroscience, Inc. (ANRO) |
| Form Type | DEF 14A |
| Filed Date | Apr 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
Alto Neuroscience filed its proxy statement for the annual meeting - shareholders vote on directors & pay.
AI Summary
Alto Neuroscience, Inc. filed its definitive proxy statement on April 1, 2025, for its annual meeting. The filing covers the fiscal year ending December 31, 2024, and details matters to be voted on by shareholders, including the election of directors and executive compensation.
Why It Matters
This filing provides shareholders with crucial information regarding company governance, director nominations, and executive compensation, enabling informed voting decisions.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material financial or operational information that would inherently increase risk.
Key Numbers
- 2024-12-31 — Fiscal Year End (The proxy statement covers the company's performance and governance for this period.)
- 20250401 — Filing Date (This is the date the definitive proxy statement was filed with the SEC.)
Key Players & Entities
- Alto Neuroscience, Inc. (company) — Registrant
- 0001999480 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- DE (company) — State of Incorporation
- 1231 (company) — Fiscal Year End
- 001-41944 (company) — SEC File Number
- 650 CASTRO STREET, SUITE 450 (company) — Business Address
- MOUNTAIN VIEW (company) — City
- CA (company) — State
- 94041 (company) — ZIP Code
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit shareholder votes on important matters such as the election of directors, executive compensation, and other corporate actions.
When does the fiscal year covered by this proxy statement end?
The fiscal year covered by this proxy statement ends on December 31, 2024.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 1, 2025.
What is Alto Neuroscience, Inc.'s Standard Industrial Classification code?
Alto Neuroscience, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Alto Neuroscience, Inc. headquartered?
Alto Neuroscience, Inc. is headquartered at 650 Castro Street, Suite 450, Mountain View, CA 94041.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 1, 2025 regarding Alto Neuroscience, Inc. (ANRO).